How does Cencora (COR) make money?

Cencora (COR) generates revenue primarily from Pharmaceutical Distribution, which accounted for 86.4% of total revenue in TTM through Q1 2026. The company reported $328.68B in revenue and converted 0.8% of it into net profit, equivalent to roughly $2.55B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Cencora (COR)?

Cencora (COR) reported a gross profit margin of 3.5% in TTM through Q1 2026, equivalent to $11.40B in gross profit on $328.68B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Cencora (COR)?

Cencora (COR) reported an operating profit margin of 1.3% in TTM through Q1 2026, equivalent to $4.20B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Cencora (COR)?

Cencora (COR) reported a net profit margin of 0.8% in TTM through Q1 2026, equivalent to $2.55B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Cencora (COR) profitable?

Yes. Cencora (COR) reported $2.55B in net income for TTM through Q1 2026, with a net profit margin of 0.8%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Cencora (COR) spend on capital expenditures?

Cencora (COR) spent $718.02M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 0.2% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Cencora (COR) generate?

Cencora (COR) generated $1.56B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 0.5%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Cencora (COR)?

Cencora (COR) had an effective tax rate of 27.2% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Cencora (COR)?

Cencora (COR) reports revenue across 4 reportable product segments, led by Pharmaceutical Distribution at 86.4% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Cencora (COR) generate most of its revenue?

U.S. Healthcare Solutions is the largest geographic market for Cencora (COR), accounting for 90.5% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Cencora Makes Money: 2026 Visual Revenue Map

Cencora (COR) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 6, 2026).

Cencora (COR) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Cencora (COR) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Pharmaceutical Distribution	$284.09B	86.4%
International Healthcare Solutions	$30.68B	9.3%
Animal Health	$11.42B	3.5%
Other Segments	$2.49B	0.8%
Total	$328.68B	100%

Pharmaceutical Distribution$284.09B
International Healthcare Solutions$30.68B
Animal Health$11.42B
Other Segments$2.49B
Total$328.68B

Cencora (COR) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Cencora (COR), TTM through Q1 2026
Region	Revenue (USD)	% of total
U.S. Healthcare Solutions	$293.64B	90.5%
International Healthcare Solutions	$30.93B	9.5%
Total	$324.57B	100%

U.S. Healthcare Solutions
International Healthcare Solutions
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Cencora (COR) reports revenue across 4 operating segments; the largest segment was Pharmaceutical Distribution at 86.4%, followed by International Healthcare Solutions (9.3%) and Animal Health (3.5%). Separately, by end-market geography, U.S. Healthcare Solutions accounted for 90.5% of revenue, followed by International Healthcare Solutions (9.5%).

Frequently asked questions

Data & methodology

Cencora (COR) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation